Callan Family Office LLC Sells 46,071 Shares of Novo Nordisk A/S $NVO

Callan Family Office LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 42.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 62,521 shares of the company’s stock after selling 46,071 shares during the quarter. Callan Family Office LLC’s holdings in Novo Nordisk A/S were worth $3,469,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC raised its stake in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares during the last quarter. NewSquare Capital LLC increased its holdings in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Guerra Advisors Inc bought a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $25,000. Mid American Wealth Advisory Group Inc. bought a new position in Novo Nordisk A/S during the 2nd quarter valued at approximately $37,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $50.35 on Wednesday. The company’s fifty day moving average price is $53.78 and its 200-day moving average price is $54.18. The stock has a market cap of $224.79 billion, a PE ratio of 14.64 and a beta of 0.67. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on NVO. Jefferies Financial Group began coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. HSBC reissued a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Morgan Stanley reaffirmed an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Finally, BMO Capital Markets set a $57.00 price target on shares of Novo Nordisk A/S in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $57.79.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Quarterly results beat expectations — Novo reported $1.01 EPS and $12.43B revenue for the quarter, topping analyst estimates and showing strong profitability metrics. MarketBeat: NVO
• Positive Sentiment: Late‑stage trial success — CagriSema outperformed semaglutide in a 68‑week type‑2 diabetes study (better HbA1c and weight loss), supporting pipeline value beyond current GLP‑1 products. Reuters: CagriSema trial
• Positive Sentiment: Full‑year 2025 sales topped forecasts — reported full‑year sales beat expectations, showing underlying demand despite competitive pressures. Barron’s: 2025 sales beat
• Neutral Sentiment: U.S. leadership changes announced — Jamey Millar named head of U.S. business (and Hong Chow head of product/portfolio strategy); routine exec moves that may affect execution but are not immediate catalysts. Reuters: U.S. appointments
• Neutral Sentiment: Analyst views mixed — some firms (e.g., Kepler) maintain positive ratings while banks (Citi) caution that more head‑to‑head data vs. competitors will matter for longer‑term positioning. Globe and Mail: Kepler rating Proactive: Citi comment
• Negative Sentiment: Bearish 2026 guidance — management forecast adjusted sales and operating profit could decline 5%–13% (constant FX) in 2026, citing U.S. price reductions and loss of exclusivity for Wegovy/Ozempic; this is the main driver of the share drop. MarketWatch: 2026 sales outlook Proactive: warns of 2026 decline
• Negative Sentiment: Pricing and competition risk — U.S. GLP‑1 prices are falling and competition (including cash‑pay channels) is intensifying, which tightens long‑term obesity market revenue potential. Reuters: Obesity market outlook

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.